CD274 and neoplasm: In contrast, atezolizumab was approved by FDA for first line therapy in cisplatin-ineligible patients with PD-L1 tumor proportion score of at least 5% or independent of PD-L1 expression for any platinum-ineligible patients but the indication was withdrawn voluntarily in November 2022.